XML 19 R33.htm IDEA: XBRL DOCUMENT v3.19.3
Financing (Tables)
9 Months Ended
Sep. 27, 2019
Debt Disclosure [Abstract]  
Components Of Debt The following summarizes the key terms of the offering (€ in millions):
 
Aggregate Principal Amount
 
Stated Annual Interest Rate
 
Issue Price (as % of Principal Amount)
 
Maturity Date
 
Interest Payment Dates (in arrears)
2026 Biopharma Euronotes
1,250.0

 
0.200
%
 
99.833
%
 
March 18, 2026
 
March 18
2028 Biopharma Euronotes
1,250.0

 
0.450
%
 
99.751
%
 
March 18, 2028
 
March 18
2031 Biopharma Euronotes
1,750.0

 
0.750
%
 
99.920
%
 
September 18, 2031
 
September 18
2039 Biopharma Euronotes
1,250.0

 
1.350
%
 
99.461
%
 
September 18, 2039
 
September 18
2049 Biopharma Euronotes
750.0

 
1.800
%
 
99.564
%
 
September 18, 2049
 
September 18

The components of the Company’s debt were as follows ($ in millions):
 
September 27, 2019
 
December 31, 2018
U.S. dollar-denominated commercial paper
$

 
$
72.8

Euro-denominated commercial paper (€2.7 billion and €2.1 billion, respectively)
2,933.2

 
2,377.5

1.0% senior unsecured notes due 2019 (€600.0 million aggregate principal amount) (the “2019 Euronotes”)

 
687.0

2.4% senior unsecured notes due 2020
499.2

 
498.5

5.0% senior unsecured notes due 2020 (the “2020 Assumed Pall Notes”)
382.8

 
386.7

Zero-coupon LYONs due 2021
34.6

 
56.2

0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”)
277.6

 
273.2

1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”)
872.6

 
913.2

Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”)
272.9

 
285.7

Envista senior unsecured term loan facility due 2022 (the “Envista Term Loan Facility”)
648.6

 

Envista senior unsecured term loan facility due 2022 (€600.0 million aggregate principal amount) (the “Envista Euro Term Loan Facility”)
655.6

 

0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”)
546.0

 
550.7

2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”)
871.7

 
912.6

3.35% senior unsecured notes due 2025
497.1

 
496.8

0.2% senior unsecured notes due 2026 (€1.3 billion aggregate principal amount) (the “2026 Biopharma Euronotes”)
1,357.5

 

0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”)
284.4

 
279.9

1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”)
651.5

 
682.0

0.45% senior unsecured notes due 2028 (€1.3 billion aggregate principal amount) (the “2028 Biopharma Euronotes”)
1,355.6

 

1.125% senior unsecured bonds due 2028 (CHF 210.0 million aggregate principal amount) (the “2028 CHF Bonds”)
216.0

 
218.1

0.75% senior unsecured notes due 2031 (€1.8 billion aggregate principal amount) (the “2031 Biopharma Euronotes”)
1,900.7

 

0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”)
491.1

 
483.4

1.35% senior unsecured notes due 2039 (€1.3 billion aggregate principal amount) (the “2039 Biopharma Euronotes”)
1,349.2

 

4.375% senior unsecured notes due 2045
499.4

 
499.3

1.8% senior unsecured notes due 2049 (€750.0 million aggregate principal amount) (the “2049 Biopharma Euronotes”)
810.3

 

Other
197.2

 
66.7

Total debt
17,604.8

 
9,740.3

Less: currently payable
1,068.6

 
51.8

Long-term debt
$
16,536.2

 
$
9,688.5